Efficacy of ezetimibe is associated with gender and baseline lipid levels in patients with type 2 diabetes

Journal of Atherosclerosis and Thrombosis

Volumn 19, Issue 9, 2012, Pages 846-853

  Shigematsu, Erina ^a   Yamakawa, Tadashi ^a   Taguri, Masataka ^a   Morita, Satoshi ^a   Tokui, Mikiya ^b   Miyamoto, Kazunori ^b   Funae, Osamu ^b   Takatuka, Yoji ^c   Kadonosono, Kazuaki ^a   Shigematsu, Hiroshi ^d   Terauchi, Yasuo ^e  

^a YOKOHAMA CITY UNIVERSITY MEDICAL CENTER   (Japan)

^b Tokui Medical Clinic   (Japan)

^c Motomachi Takatuka Medical Clinic   (Japan)

^d Sato Clinic   (Japan)

^e YOKOHAMA CITY UNIVERSITY   (Japan)

Author keywords

Diabetes mellitus; Ezetimibe; Total cholesterol; Triglycerides

Indexed keywords

EZETIMIBE; HEMOGLOBIN A1C; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL;

ADD ON THERAPY; ADULT; AGED; ARTICLE; BODY MASS; CHOLESTEROL INTAKE; DRUG EFFICACY; FEMALE; GENDER; HUMAN; LIPID BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; TREATMENT DURATION; TREATMENT RESPONSE;

AGED; AZETIDINES; BODY MASS INDEX; CHOLESTEROL; CHOLESTEROL, LDL; DIABETES MELLITUS, TYPE 2; FEMALE; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERCHOLESTEROLEMIA; LIPIDS; MALE; MIDDLE AGED; SEX FACTORS; TRIGLYCERIDES;

EID: 84867905311     PISSN: 13403478     EISSN: 18803873     Source Type: Journal    
DOI: 10.5551/jat.12799     Document Type: Article

References (31)

1. Teramoto T, Sasaki J, Ueshima H, Egusa G, Kinoshita M, Shimamoto K, et al: Executive summary of Japan Atherosclerosis Society (JAS) guideline for diagnosis and prevention of atherosclerotic cardiovascular diseases for Japanese. J Atheroscler Thromb, 2007; 14: 45-50
2. Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). JAMA, 2001; 285: 2486-2497
3. Haffner SM: Dyslipidemia management in adults with diabetes. Diabetes Care, 2004; 27 Suppl 1: S68-S71
4. Dembowski E, Davidson MH: Statin and ezetimibe combination therapy in cardiovascular disease. Curr Opin Endocrinol Diabetes Obes, 2009; 16: 183-188
5. Davis HR Jr, Compton DS, Hoos L, Tetzloff G: Ezetimibe, a potent cholesterol absorption inhibitor, inhibits the development of atherosclerosis in ApoE knockout mice. Arterioscler Thromb Vasc Biol, 2001; 21: 2032-2038
6. Garcia-Calvo M, Lisnock J, Bull HG, Hawes BE, Burnett DA, Braun MP, et al: The target of ezetimibe is Niemann-Pick C1-Like 1 (NPC1L1). Proc Natl Acad Sci U S A, 2005; 102: 8132-8137
7. Knopp RH, Dujovne CA, Le Beaut A, Lipka LJ, Suresh R, Veltri EP: Evaluation of the efficacy, safety, and tolerability of ezetimibe in primary hypercholesterolaemia: a pooled analysis from two controlled phase III clinical studies. Int J Clin Pract 2003; 57: 363-368
8. Miettinen HE, Gylling H, Tenhunen J, Virtamo J, Jauhiainen M, Huttunen JK, et al: Molecular genetic study of Finns with hypoalphalipoproteinemia and hyperalphalipoproteinemia: a novel Gly230 Arg mutation (LCAT[Fin]) of lecithin: cholesterol acyltransferase (LCAT) accounts for 5% of cases with very low serum HDL cholesterol levels. Arterioscler Thromb Vasc Biol, 1998; 18: 591-598
9. Strandberg TE, Tilvis RS, Pitkala KH, Miettinen TA: Cholesterol and glucose metabolism and recurrent cardiovascular events among the elderly: a prospective study. J Am Coll Cardiol, 2006; 48: 708-714
10. Sudhop T, Lutjohann D, Kodal A, Igel M, Tribble DL, Shah S, et al: Inhibition of intestinal cholesterol absorption by ezetimibe in humans. Circulation, 2002; 106: 1943-1948
11. Hegele RA, Guy J, Ban MR, Wang J: NPC1L1 haplotype is associated with inter-individual variation in plasma lowdensity lipoprotein response to ezetimibe. Lipids Health Dis, 2005; 4: 16
12. Simon JS, Karnoub MC, Devlin DJ, Arreaza MG, Qiu P, Monks SA, et al: Sequence variation in NPC1L1 and association with improved LDL-cholesterol lowering in response to ezetimibe treatment. Genomics, 2005; 86: 648-656
13. Gylling H, Miettinen TA: Cholesterol absorption and lipoprotein metabolism in type II diabetes mellitus with and without coronary artery disease. Atherosclerosis, 1996; 126: 325-332
14. Mok HY, von Bergmann K, Grundy SM: Effects of continuous and intermittent feeding on biliary lipid outputs in man: application for measurements of intestinal absorption of cholesterol and bile acids. J Lipid Res, 1979; 20: 389-398
15. Lally S, Tan CY, Owens D, Tomkin GH: Messenger RNA levels of genes involved in dysregulation of postprandial lipoproteins in type 2 diabetes: the role of Niemann-Pick C1-like 1, ATP-binding cassette, transporters G5 and G8, and of microsomal triglyceride transfer protein. Diabetologia, 2006; 49: 1008-1016
16. Report of the Committee on the classification and diagnostic criteria of diabetes mellitus. J Jpn Diabetes Soc, 2010; 53: 450-467
17. Report of the subdivision on Resources TcfSaT, Ministry of Education, Culture, Sports, Science and Technology, Japan, editor. Standard Tables of Food Composition in Japan. Tokyo: national printign bureau, 2005
18. Okada K, Yagyu H, Kotani K, Miyamoto M, Osuga J, Nagasaka S, et al: Lipid-lowering effects of ezetimibe for hypercholesterolemic patients with and without type 2 diabetes mellitus. Endocr J, 2010; 57: 903-908
19. Kishimoto M, Sugiyama T, Osame K, Takarabe D, Oka moto M, Noda M: Efficacy of ezetimibe as monotherapy or combination therapy in hypercholesterolemic patients with and without diabetes. J Med Invest, 2011; 58: 86-94
20. Pearson TA, Denke MA, McBride PE, Battisti WP, Brady WE, Palmisano J: A community-based, randomized trial of ezetimibe added to statin therapy to attain NCEP ATP III goals for LDL cholesterol in hypercholesterolemic patients: the ezetimibe add-on to statin for effectiveness (EASE) trial. Mayo Clin Proc, 2005; 80: 587-595
21. Miettinen TA, Gylling H: Cholesterol synthesis and absorption in coronary patients with lipid triad and isolated high LDL cholesterol in a 4S subgroup. Atherosclerosis, 2003; 168: 343-349
22. Ose L, Shah A, Davies MJ, Rotonda J, Maccubbin D, Tribble D, et al: Consistency of lipid-altering effects of ezetimibe/simvastatin across gender, race, age, baseline low density lipoprotein cholesterol levels, and coronary heart disease status: results of a pooled retrospective analysis. Curr Med Res Opin, 2006; 22: 823-835
23. Bays HE, Conard SE, Leiter LA, Bird SR, Lowe RS, Tershakovec AM: Influence of age, gender, and race on the efficacy of adding ezetimibe to atorvastatin vs. atorvastatin up-titration in patients at moderately high or high risk for coronary heart disease. Int J Cardiol, 2010 Sep 11
24. Conard SE, Bays HE, Leiter LA, Bird SR, Rubino J, Lowe RS, et al: Efficacy and safety of ezetimibe added on to atorvastatin (20 mg) versus uptitration of atorvastatin (to 40 mg) in hypercholesterolemic patients at moderately high risk for coronary heart disease. Am J Cardiol, 2008; 102: 1489-1494
25. The outline of a National Health and Nutrition Examination Survey Ministry of Health, Labour, and Welfare. Heisei 20 Report 2009: 1-45
26. Chirinos JA, Williams MM, Bregman DB, Ashfaq H, Khayyam U, Iqbal N: Efficacy of cholesterol uptake inhibition added to statin therapy among subjects following a low-carbohydrate diet: a randomized controlled trial. Am Heart J, 2010; 159: 918 e1-e6
27. Tomkin GH: Targets for intervention in dyslipidemia in diabetes. Diabetes Care, 2008; 31 Suppl 2: S241-S248
28. Gazi IF, Tsimihodimos V, Tselepis AD, Elisaf M, Mikhailidis DP: Clinical importance and therapeutic modulation of small dense low-density lipoprotein particles. Expert Opin Biol Ther, 2007; 7: 53-72
29. Fras Z, Mikhailidis DP: Statin plus ezetimibe treatment in clinical practice: the SI-SPECT (Slovenia (SI) Statin Plus Ezetimibe in Cholesterol Treatment) monitoring of clinical practice study. Curr Med Res Opin, 2008; 24: 2467-2476
30. Ruggenenti P, Cattaneo D, Rota S, Iliev I, Parvanova A, Diadei O, et al: Effects of combined ezetimibe and simvastatin therapy as compared with simvastatin alone in patients with type 2 diabetes: a prospective randomized double-blind clinical trial. Diabetes Care, 2010; 33: 1954-1956
31. Leiter LA, Bays H, Conard S, Bird S, Rubino J, Hanson ME, et al: Efficacy and safety of ezetimibe added on to atorvastatin (40 mg) compared with uptitration of atorvastatin (to 80 mg) in hypercholesterolemic patients at high risk of coronary heart disease. Am J Cardiol, 2008; 102: 1495-1501